BSX Quote, Financials, Valuation and Earnings

Baxter International has a net margin of 14.45% compared to Boston Scientific's net margin of 4.8%. Boston Scientific's return on equity of 9.57% beat Baxter International's return on equity of -7.38%.

Boston Scientific has a consensus price target of $117.45, signalling upside risk potential of 13.09%. On the other hand Baxter International has an analysts' consensus of $38.09 which suggests that it could grow by 28.26%. Given that Baxter International has higher upside potential than Boston Scientific, analysts believe Baxter International is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.679, which suggesting that the stock is 32.134% less volatile than S&P 500. In comparison Baxter International has a beta of 0.610, suggesting its less volatile than the S&P 500 by 38.958%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.69% to investors and pays a quarterly dividend of $0.17 per share. Boston Scientific pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.7B, which are larger than Baxter International quarterly revenues of $2.6B. Boston Scientific's net income of $674M is higher than Baxter International's net income of $126M. Notably, Boston Scientific's price-to-earnings ratio is 75.81x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.81x versus 1.28x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 14.45% compared to Boston Scientific's net margin of 30.99%. Boston Scientific's return on equity of 9.57% beat Intuitive Surgical's return on equity of 15.82%.

Boston Scientific has a consensus price target of $117.45, signalling upside risk potential of 13.09%. On the other hand Intuitive Surgical has an analysts' consensus of $578.35 which suggests that it could grow by 9.94%. Given that Boston Scientific has higher upside potential than Intuitive Surgical, analysts believe Boston Scientific is more attractive than Intuitive Surgical.

Boston Scientific has a beta of 0.679, which suggesting that the stock is 32.134% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.249%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.7B, which are larger than Intuitive Surgical quarterly revenues of $2.3B. Boston Scientific's net income of $674M is lower than Intuitive Surgical's net income of $698.4M. Notably, Boston Scientific's price-to-earnings ratio is 75.81x while Intuitive Surgical's PE ratio is 77.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.81x versus 21.91x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of 14.45% compared to Boston Scientific's net margin of -5.14%. Boston Scientific's return on equity of 9.57% beat Integer Holdings's return on equity of 4.85%.

Boston Scientific has a consensus price target of $117.45, signalling upside risk potential of 13.09%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 22.16%. Given that Integer Holdings has higher upside potential than Boston Scientific, analysts believe Integer Holdings is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.679, which suggesting that the stock is 32.134% less volatile than S&P 500. In comparison Integer Holdings has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.988%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.7B, which are larger than Integer Holdings quarterly revenues of $437.4M. Boston Scientific's net income of $674M is higher than Integer Holdings's net income of -$22.5M. Notably, Boston Scientific's price-to-earnings ratio is 75.81x while Integer Holdings's PE ratio is 57.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.81x versus 2.46x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 14.45% compared to Boston Scientific's net margin of 11.15%. Boston Scientific's return on equity of 9.57% beat Stryker's return on equity of 14.2%.

Boston Scientific has a consensus price target of $117.45, signalling upside risk potential of 13.09%. On the other hand Stryker has an analysts' consensus of $422.35 which suggests that it could grow by 6.99%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

Boston Scientific has a beta of 0.679, which suggesting that the stock is 32.134% less volatile than S&P 500. In comparison Stryker has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.528%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.84% to investors and pays a quarterly dividend of $0.84 per share. Boston Scientific pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.7B, which are smaller than Stryker quarterly revenues of $5.9B. Boston Scientific's net income of $674M is higher than Stryker's net income of $654M. Notably, Boston Scientific's price-to-earnings ratio is 75.81x while Stryker's PE ratio is 53.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.81x versus 6.56x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.